First Biosimilar to Lucentis Gets FDA Approval
The approval of Byooviz was based on a review of evidence demonstrating a high degree of similarity to the reference product.
Miscellaneous Ocular Agents
Tebentafusp Gets Priority Review for Metastatic Uveal Melanoma
The application is supported by data from the phase 2 IMCgp100-202 trial that assessed tebentafusp in 378 HLA-A*02:01-positive adults with previously untreated metastatic uveal melanoma.
NSAID Eye Drops May Suffice for Cataract Surgery Prophylaxis
Initiation of prophylactic treatment 3 days before surgery is not superior to initiation on day of surgery
Intravitreal Methotrexate Gets Orphan Drug Status for Retinitis Pigmentosa
The FDA has granted Orphan Drug designation to ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa.
Atropine Plus Patching Ups Visual Acuity in Amblyopic Eye
Visual acuity of the affected eye improved more with atropine plus patching than patching alone in children with severe amblyopia
Current Use of Hormonal Contraceptives May Up Glaucoma Risk
Authors say risk for glaucoma is low and should not discourage use of hormonal contraceptives
One-Quarter in Ocular HTN Treatment Study Developed Visual Field Loss
20-year cumulative incidence of primary open angle glaucoma was 45.6 percent after adjustment for exposure time
Study Examines Patient Perceptions of Marijuana as Glaucoma Treatment
Research shows patients with glaucoma are likely to encounter conflicting opinions on marijuana’s role in glaucoma therapy, especially from dispensaries.
Evaluating Reluctance to Embrace Selective Laser Trabeculoplasty as Front-Line Therapy
A growing body of research shows SLT for first-line glaucoma therapy works as well as drops — so why aren’t clinician’s embracing it?
TECNIS Eyhance Intraocular Lens Approved for Cataract Patients
The new approvals are the latest in Johnson & Johnson’s IOLs; the Company claims the new TECNIS Eyhance IOL can slightly extend the depth of focus and deliver better image contrast.
